Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.37 |
| ▸ | ESR1 | P03372 | 2/20 | 0.35 |
| ▸ | PARG | Q86W56 | 4/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CDC25B | P30305 | 1/20 | 0.32 |
| ▸ | TERT | O14746 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL61260 | 0.91 | PARG (0.49) | SLC6A2SLC6A4KCNH2SLC6A3GAA | |
| SCHEMBL6113938 | 0.86 | KDM4E (0.47) | SLC6A2SLC6A4KCNH2SLC6A3GAA | |
| SCHEMBL29558657 | 0.86 | KDM4E (0.47) | SLC6A2SLC6A4KCNH2SLC6A3GAA | |
| SCHEMBL29558779 | 0.80 | ALDH1A1 (0.40) | SLC6A2SLC6A4KCNH2SLC6A3GAA | |
| SCHEMBL90647 | 0.80 | ALDH1A1 (0.40) | SLC6A2SLC6A4KCNH2SLC6A3GAA | |
| SCHEMBL8768025 | 0.80 | ALDH1A1 (0.40) | SLC6A2SLC6A4KCNH2SLC6A3GAA | |
| SCHEMBL13366897 | 0.77 | ALDH1A1 (0.36) | PARGTSHRHTTSMN1; SMN2 | |
| SCHEMBL55488 | 0.74 | TDP2 (0.40) | GAAPARGCDC25B | |
| SCHEMBL60256 | 0.67 | PARG (0.72) | PARGSMN1; SMN2TDP1 | |
| SCHEMBL28861105 | 0.61 | SRC (0.42) | GAASMN1; SMN2TERT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108314663-B | Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof | 多格伍德药品公司 | 2022-05-13 | — | — | CN | disclosed |
| US-9446021-B2 | Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof | DOGWOOD PHARMACEUTICALS, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-9446021-B2 | Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof | DOGWOOD PHARMACEUTICALS, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-9446021-B2 | Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof | DOGWOOD PHARMACEUTICALS, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| EP-2152258-B1 | DERIVATIVES OF FLUORENE, ANTHRACENE, XANTHENE, DIBENZOSUBERONE AND ACRIDINE AND USES THEREOF | AVALON PHARMACEUTICALS (US) | 2016-05-04 | — | — | EP | disclosed |
| US-20150313873-A1 | Derivatives of Fluorene, Anthracene, Xanthene, Dibenzosuberone and Acridine and Uses Thereof | DOGWOOD PHARMACEUTICALS, INC. | 2015-11-05 | — | — | US | disclosed |
| US-20150313873-A1 | Derivatives of Fluorene, Anthracene, Xanthene, Dibenzosuberone and Acridine and Uses Thereof | DOGWOOD PHARMACEUTICALS, INC. | 2015-11-05 | — | — | US | disclosed |
| US-20150313873-A1 | Derivatives of Fluorene, Anthracene, Xanthene, Dibenzosuberone and Acridine and Uses Thereof | DOGWOOD PHARMACEUTICALS, INC. | 2015-11-05 | — | — | US | disclosed |
| US-9120754-B2 | Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof | DOGWOOD PHARMACEUTICALS, INC. (US) | 2015-09-01 | — | — | US | disclosed |
| US-9120754-B2 | Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof | DOGWOOD PHARMACEUTICALS, INC. (US) | 2015-09-01 | — | — | US | disclosed |
| US-9120754-B2 | Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof | DOGWOOD PHARMACEUTICALS, INC. (US) | 2015-09-01 | — | — | US | disclosed |
| US-20120129837-A1 | Derivatives of Fluorene, Anthracene, Xanthene, Dibenzosuberone and Acridine and Uses Thereof | ALLERGAN SALES, LLC | 2012-05-24 | — | — | US | disclosed |
| US-20120129837-A1 | Derivatives of Fluorene, Anthracene, Xanthene, Dibenzosuberone and Acridine and Uses Thereof | ALLERGAN SALES, LLC | 2012-05-24 | — | — | US | disclosed |
| US-20120129837-A1 | Derivatives of Fluorene, Anthracene, Xanthene, Dibenzosuberone and Acridine and Uses Thereof | ALLERGAN SALES, LLC | 2012-05-24 | — | — | US | disclosed |
| US-8129519-B2 | Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof | ALLERGAN SALES, LLC | 2012-03-06 | — | — | US | disclosed |
| US-8129519-B2 | Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof | ALLERGAN SALES, LLC | 2012-03-06 | — | — | US | disclosed |
| WO-2010082912-A1 | DERIVATIVES OF MULTI-RING AROMATIC COMPOUNDS AND USES AS ANTI-TUMOR AGENTS | AVALON PHARMACEUTICALS (US) | 2010-07-22 | — | — | WO | disclosed |
| US-20100137354-A1 | DERIVATIVES OF FLUORENE, ANTHRACENE, XANTHENE, DIBENZOSUBERONE AND ACRIDINE AND USES THEREOF | ALLERGAN SALES, LLC | 2010-06-03 | — | — | US | disclosed |
| US-20100137354-A1 | DERIVATIVES OF FLUORENE, ANTHRACENE, XANTHENE, DIBENZOSUBERONE AND ACRIDINE AND USES THEREOF | ALLERGAN SALES, LLC | 2010-06-03 | — | — | US | disclosed |
| WO-2010059142-A1 | ANTHRAQUINONE DIOXIMES AND USES THEREOF | AVALON PHARMACEUTICALS (US) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129837-A1 | Derivatives of Fluorene, Anthracene, Xanthene, Dibenzosuberone and Acridine and Uses Thereof | WNT1, CTNND1, CTNNB1 | SLC6A2 4191/4885SLC6A4 2550/4885KCNH2 3522/4885 |
| US-20150313873-A1 | Derivatives of Fluorene, Anthracene, Xanthene, Dibenzosuberone and Acridine and Uses Thereof | WNT1, CTNND1, CTNNB1 | SLC6A2 4191/4885SLC6A4 2550/4885KCNH2 3522/4885 |
| US-20100137354-A1 | DERIVATIVES OF FLUORENE, ANTHRACENE, XANTHENE, DIBENZOSUBERONE AND ACRIDINE AND USES THEREOF | WNT1, CTNND1, CTNNB1 | SLC6A2 4191/4885SLC6A4 2550/4885KCNH2 3522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.